NO316745B1 - Mikrofluidiserte partikler av atovaquon, farmasoytisk preparat inneholdende slike partikler, fremgangsmate for deres fremstilling og fremgangsmate for fremstilling av preparatet - Google Patents
Mikrofluidiserte partikler av atovaquon, farmasoytisk preparat inneholdende slike partikler, fremgangsmate for deres fremstilling og fremgangsmate for fremstilling av preparatet Download PDFInfo
- Publication number
- NO316745B1 NO316745B1 NO19952522A NO952522A NO316745B1 NO 316745 B1 NO316745 B1 NO 316745B1 NO 19952522 A NO19952522 A NO 19952522A NO 952522 A NO952522 A NO 952522A NO 316745 B1 NO316745 B1 NO 316745B1
- Authority
- NO
- Norway
- Prior art keywords
- atovaquone
- particles
- preparation
- pharmaceutical preparation
- mixture
- Prior art date
Links
- KUCQYCKVKVOKAY-CTYIDZIISA-N atovaquone Chemical compound C1([C@H]2CC[C@@H](CC2)C2=C(C(C3=CC=CC=C3C2=O)=O)O)=CC=C(Cl)C=C1 KUCQYCKVKVOKAY-CTYIDZIISA-N 0.000 title claims description 38
- 229960003159 atovaquone Drugs 0.000 title claims description 38
- 239000002245 particle Substances 0.000 title claims description 32
- 238000000034 method Methods 0.000 title claims description 18
- 238000002360 preparation method Methods 0.000 title claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 claims description 17
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 239000000375 suspending agent Substances 0.000 claims description 7
- 239000000725 suspension Substances 0.000 claims description 7
- 239000003981 vehicle Substances 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000004094 surface-active agent Substances 0.000 claims description 5
- 239000000230 xanthan gum Substances 0.000 claims description 4
- 229920001285 xanthan gum Polymers 0.000 claims description 4
- 229940082509 xanthan gum Drugs 0.000 claims description 4
- 235000010493 xanthan gum Nutrition 0.000 claims description 4
- 238000011321 prophylaxis Methods 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims description 2
- 241000233872 Pneumocystis carinii Species 0.000 claims description 2
- 208000010362 Protozoan Infections Diseases 0.000 claims description 2
- 230000003071 parasitic effect Effects 0.000 claims description 2
- 229920001993 poloxamer 188 Polymers 0.000 claims description 2
- 229940044519 poloxamer 188 Drugs 0.000 claims description 2
- -1 polyethylene Polymers 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims 1
- 229920000573 polyethylene Polymers 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 6
- 239000012634 fragment Substances 0.000 description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 201000005485 Toxoplasmosis Diseases 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- BSJMWHQBCZFXBR-UHFFFAOYSA-N 3-[4-(p-chlorophenyl)cyclohexyl]-4-hydroxy-1,2-naphthoquinone Chemical compound O=C1C(=O)C2=CC=CC=C2C(O)=C1C(CC1)CCC1C1=CC=C(Cl)C=C1 BSJMWHQBCZFXBR-UHFFFAOYSA-N 0.000 description 1
- 208000003495 Coccidiosis Diseases 0.000 description 1
- 208000008953 Cryptosporidiosis Diseases 0.000 description 1
- 206010011502 Cryptosporidiosis infection Diseases 0.000 description 1
- 241000223924 Eimeria Species 0.000 description 1
- 241000223931 Eimeria acervulina Species 0.000 description 1
- 206010023076 Isosporiasis Diseases 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 208000005384 Pneumocystis Pneumonia Diseases 0.000 description 1
- 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 description 1
- 241000223777 Theileria Species 0.000 description 1
- 241000223778 Theileria annulata Species 0.000 description 1
- 241000223779 Theileria parva Species 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000000842 anti-protozoal effect Effects 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004262 dental pulp cavity Anatomy 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
- Fertilizers (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929226905A GB9226905D0 (en) | 1992-12-24 | 1992-12-24 | Pharmaceutical preparation |
| PCT/GB1993/002646 WO1994014426A1 (fr) | 1992-12-24 | 1993-12-23 | Compositions pharmaceutiques a base d'atovaquone |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO952522L NO952522L (no) | 1995-06-22 |
| NO952522D0 NO952522D0 (no) | 1995-06-22 |
| NO316745B1 true NO316745B1 (no) | 2004-04-26 |
Family
ID=10727175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19952522A NO316745B1 (no) | 1992-12-24 | 1995-06-22 | Mikrofluidiserte partikler av atovaquon, farmasoytisk preparat inneholdende slike partikler, fremgangsmate for deres fremstilling og fremgangsmate for fremstilling av preparatet |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US6018080A (fr) |
| EP (1) | EP0675711B1 (fr) |
| JP (1) | JP3461353B2 (fr) |
| KR (1) | KR0175193B1 (fr) |
| CN (1) | CN1076194C (fr) |
| AT (1) | ATE169215T1 (fr) |
| AU (2) | AU675102B2 (fr) |
| BG (1) | BG61932B1 (fr) |
| BR (1) | BR9307719A (fr) |
| CA (1) | CA2152615C (fr) |
| CZ (1) | CZ289701B6 (fr) |
| DE (1) | DE69320208T2 (fr) |
| DK (1) | DK0675711T3 (fr) |
| ES (1) | ES2122223T3 (fr) |
| FI (1) | FI114007B (fr) |
| GB (1) | GB9226905D0 (fr) |
| GE (1) | GEP19991515B (fr) |
| HK (1) | HK1004086A1 (fr) |
| HR (1) | HRP931516B1 (fr) |
| HU (1) | HU220215B (fr) |
| IL (1) | IL108154A (fr) |
| MY (1) | MY109990A (fr) |
| NO (1) | NO316745B1 (fr) |
| NZ (1) | NZ258995A (fr) |
| PL (1) | PL175374B1 (fr) |
| RO (1) | RO119686B1 (fr) |
| RU (1) | RU2127585C1 (fr) |
| SA (1) | SA94140644B1 (fr) |
| SG (1) | SG43901A1 (fr) |
| SI (1) | SI9300678A (fr) |
| SK (1) | SK281924B6 (fr) |
| TW (2) | TW514531B (fr) |
| UA (1) | UA39879C2 (fr) |
| WO (1) | WO1994014426A1 (fr) |
| YU (1) | YU48919B (fr) |
| ZA (1) | ZA939673B (fr) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9224739D0 (en) * | 1992-11-26 | 1993-01-13 | Wellcome Found | Medicaments |
| GB9226905D0 (en) * | 1992-12-24 | 1993-02-17 | Wellcome Found | Pharmaceutical preparation |
| AU3705695A (en) * | 1994-10-26 | 1996-05-23 | Wellcome Foundation Limited, The | Pharmaceutical composition comprising atovaquone |
| DE4440337A1 (de) * | 1994-11-11 | 1996-05-15 | Dds Drug Delivery Services Ges | Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit |
| GB9424013D0 (en) * | 1994-11-29 | 1995-01-18 | Wellcome Found | Medicaments |
| ATE265846T1 (de) * | 1998-02-25 | 2004-05-15 | Abbott Lab | Butorphanol enthaltende formulierungen mit verzögerter freisetzung |
| US6503949B1 (en) | 1999-05-17 | 2003-01-07 | Noro Nordisk A/S | Glucagon antagonists/inverse agonists |
| US6562807B2 (en) | 2000-06-23 | 2003-05-13 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| US6821960B2 (en) | 2000-11-17 | 2004-11-23 | Noyo Nordisk Pharmaceuticals, Inc. | Glucagon antagonists/inverse agonists |
| WO2002040445A1 (fr) | 2000-11-17 | 2002-05-23 | Novo Nordisk A/S | Agonistes de glucagon/antagonistes inverses |
| US6706744B2 (en) | 2000-11-17 | 2004-03-16 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| US6762318B2 (en) | 2001-12-03 | 2004-07-13 | Novo Nordisk A/S | Glucagon antagonists |
| US6881746B2 (en) | 2001-12-03 | 2005-04-19 | Novo Nordick A/S | Glucagon antagonists/inverse agonists |
| US7183518B2 (en) * | 2004-09-24 | 2007-02-27 | Michael Near | System of food storage preparation and delivery in finished cooked state |
| DE102005011786A1 (de) * | 2005-03-11 | 2006-09-14 | Pharmasol Gmbh | Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen |
| DE502006005846D1 (de) * | 2005-04-13 | 2010-02-25 | Abbott Gmbh & Co Kg | Verfahren zur schonenden herstellung hochfeiner partikelsuspensionen und hochfeiner partikel sowie deren verwendung |
| US20080241254A1 (en) * | 2007-01-02 | 2008-10-02 | Suryakant Navale | Pharmaceutical composition comprising atovaquone particles |
| DE102007001473A1 (de) | 2007-01-08 | 2008-07-10 | Andreas Lemke | Verfahren zur Herstellung und Anwendung von Mikro- und/oder Nanosuspensionen durch aufbauende Mikronisierung in Gegenwart von Trockeneis und hohem Druck |
| WO2009007991A2 (fr) * | 2007-04-19 | 2009-01-15 | Ipca Laboratories Limited | Nouveau procédé de préparation d'atovaquone et ses nouveaux intermédiaires |
| AU2009273747A1 (en) * | 2008-07-25 | 2010-01-28 | Alphapharm Pty Ltd | Atovaquone with a particle size diameter range (D90) of greater than 3 um to about 10 um |
| US20100099776A1 (en) * | 2008-10-20 | 2010-04-22 | Ranbaxy Laboratories Limited | Oily suspension of atovaquone |
| EP2467358B1 (fr) | 2009-08-20 | 2014-07-23 | IPCA Laboratories Limited | Nouveau complexe pour le traitement et/ou la prophylaxie d'infections parasitaires |
| CA2780292A1 (fr) | 2009-11-10 | 2011-05-19 | Celgene Corporation | Nanosuspension d'un medicament mediocrement soluble par un procede de microfluidisation |
| WO2011151418A2 (fr) | 2010-06-02 | 2011-12-08 | Abbott Gmbh & Co. Kg | Formulation de nanosuspension comprenant une phase hydrophobe de polydiméthylsiloxane |
| WO2014100403A1 (fr) | 2012-12-19 | 2014-06-26 | Kashiv Pharma, Llc | Nanoparticules stabilisées super saturées pour des médicaments médiocrement solubles |
| WO2015071841A1 (fr) | 2013-11-12 | 2015-05-21 | Druggability Technologies Holdings Limited | Complexes de dabigatran et ses dérivés, procédé de préparation de ceux-ci et compositions pharmaceutiques contenant ceux-ci |
| CN109640948B (zh) * | 2016-06-16 | 2023-05-02 | 利物浦大学 | 化学组合物 |
| US20220265566A1 (en) * | 2018-10-18 | 2022-08-25 | Tulex Pharmaceuticals Inc. | Atovaquone nanoparticulate compositions |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2533648A (en) * | 1949-03-05 | 1950-12-12 | Joseph H Warburg | Circular saw making |
| NL6411993A (fr) * | 1963-10-18 | 1965-04-20 | ||
| US3347830A (en) * | 1964-07-30 | 1967-10-17 | Grace W R & Co | Process of polymerizing formaldehyde |
| GB1141735A (en) * | 1966-11-23 | 1969-01-29 | Pfizer & Co C | Pharmaceutical anti-tumor composition |
| US3655699A (en) * | 1970-03-02 | 1972-04-11 | Pfizer | Analogues of lapachol as antitumor agents |
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| DE2601458A1 (de) * | 1975-01-20 | 1976-07-22 | Ciba Geigy Ag | Loesliche, von phenylindandiaminen abgeleitete polyamide |
| EP0002228B1 (fr) * | 1977-11-22 | 1984-02-29 | The Wellcome Foundation Limited | Dérivés d'hydroxynaphtochinones, leurs préparations utilisées dans le traitement et la prévention de la theilériose chez le bétail et les moutons; leurs procédés de préparation; dérivés de naphtoquinones |
| US4485117A (en) | 1981-10-16 | 1984-11-27 | Hudson Alan T | Antiprotozoal compounds |
| US4485116A (en) * | 1981-10-16 | 1984-11-27 | Hudson Alan T | Antiprotozoal compounds |
| DE3141691A1 (de) * | 1981-10-21 | 1983-05-19 | Hoechst Ag, 6230 Frankfurt | Plasmid pac 1, verfahren zu seiner gewinnung und seine verwendung |
| GB8310140D0 (en) * | 1983-04-14 | 1983-05-18 | Wellcome Found | Antiprotozoal agents |
| US5053432A (en) * | 1983-04-14 | 1991-10-01 | Burroughs Wellcome Co. | Naphthoquinone derivatives |
| GB8310141D0 (en) * | 1983-04-14 | 1983-05-18 | Wellcome Found | Naphthoquinone derivatives |
| US5175319A (en) | 1983-04-14 | 1992-12-29 | Burroughs Wellcome Co. | Naphthoquinone derivatives |
| US4963367A (en) * | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
| PL276385A1 (en) * | 1987-01-30 | 1989-07-24 | Exxon Chemical Patents Inc | Method for polymerization of olefines,diolefins and acetylene unsaturated compounds |
| IL85097A (en) * | 1987-01-30 | 1992-02-16 | Exxon Chemical Patents Inc | Catalysts based on derivatives of a bis(cyclopentadienyl)group ivb metal compound,their preparation and their use in polymerization processes |
| US4783389A (en) * | 1987-03-27 | 1988-11-08 | E. I. Du Pont De Nemours And Company | Process for preparation of liquid electrostatic developers |
| US5155080A (en) * | 1988-07-15 | 1992-10-13 | Fina Technology, Inc. | Process and catalyst for producing syndiotactic polyolefins |
| US5225500A (en) * | 1988-07-15 | 1993-07-06 | Fina Technology, Inc. | Process and catalyst for producing syndiotactic polyolefins |
| GB8819477D0 (en) * | 1988-08-16 | 1988-09-21 | Wellcome Found | Medicaments |
| US5225184A (en) * | 1988-08-16 | 1993-07-06 | Burroughs Wellcome Co. | Medicaments |
| US5206268A (en) * | 1988-08-16 | 1993-04-27 | Burroughs Wellcome Co. | Medicaments |
| DE68914930T2 (de) * | 1988-08-16 | 1994-08-18 | Wellcome Found | Naphtochinone zur Behandlung und Prophylaxe von Pneumocystis carinii-Infektionen. |
| KR930002411B1 (ko) * | 1988-09-14 | 1993-03-30 | 미쓰이세끼유 가가꾸고오교오 가부시끼가이샤 | 벤젠불용성 유기알루미늄 옥시화합물 및 그 제조방법 |
| GB8921516D0 (en) * | 1989-09-22 | 1989-11-08 | Wellcome Found | Medicaments |
| ATE137770T1 (de) * | 1989-10-10 | 1996-05-15 | Fina Technology | Metallocenkatalysator mit lewissäure und alkylaluminium |
| GB8923254D0 (en) * | 1989-10-16 | 1989-12-06 | Wellcome Found | Medicaments |
| DE69026679T3 (de) * | 1989-10-30 | 2005-10-06 | Fina Technology, Inc., Houston | Addition von Alkylaluminium zum Verbessern eines Metallocenkatalysators |
| US5387568A (en) * | 1989-10-30 | 1995-02-07 | Fina Technology, Inc. | Preparation of metallocene catalysts for polymerization of olefins |
| DE3942363A1 (de) * | 1989-12-21 | 1991-06-27 | Hoechst Ag | Verfahren zur herstellung einer polypropylen-formmasse |
| JP2545006B2 (ja) * | 1990-07-03 | 1996-10-16 | ザ ダウ ケミカル カンパニー | 付加重合触媒 |
| JP3076619B2 (ja) | 1991-05-14 | 2000-08-14 | 三井化学株式会社 | ブロック共重合体の製造方法 |
| GB9226905D0 (en) * | 1992-12-24 | 1993-02-17 | Wellcome Found | Pharmaceutical preparation |
| US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
| US5766522A (en) * | 1996-07-19 | 1998-06-16 | Morton International, Inc. | Continuous processing of powder coating compositions |
| US5976578A (en) * | 1996-10-10 | 1999-11-02 | Mcneil-Ppc, Inc. | Liquid antacid compositions |
| US5914135A (en) * | 1997-04-16 | 1999-06-22 | Mcneil-Ppc, Inc. | Liquid antacid compositions |
-
1992
- 1992-12-24 GB GB929226905A patent/GB9226905D0/en active Pending
-
1993
- 1993-12-20 GE GEAP19931692A patent/GEP19991515B/en unknown
- 1993-12-22 YU YU80893A patent/YU48919B/sh unknown
- 1993-12-23 PL PL93309629A patent/PL175374B1/pl unknown
- 1993-12-23 CN CN93121376A patent/CN1076194C/zh not_active Expired - Fee Related
- 1993-12-23 BR BR9307719-0A patent/BR9307719A/pt not_active Application Discontinuation
- 1993-12-23 DE DE69320208T patent/DE69320208T2/de not_active Expired - Lifetime
- 1993-12-23 SG SG1996004546A patent/SG43901A1/en unknown
- 1993-12-23 RU RU95122758A patent/RU2127585C1/ru active
- 1993-12-23 CZ CZ19951451A patent/CZ289701B6/cs not_active IP Right Cessation
- 1993-12-23 CA CA002152615A patent/CA2152615C/fr not_active Expired - Lifetime
- 1993-12-23 JP JP51496894A patent/JP3461353B2/ja not_active Expired - Lifetime
- 1993-12-23 SI SI9300678A patent/SI9300678A/sl unknown
- 1993-12-23 KR KR1019950702217A patent/KR0175193B1/ko not_active IP Right Cessation
- 1993-12-23 ZA ZA939673A patent/ZA939673B/xx unknown
- 1993-12-23 AU AU57105/94A patent/AU675102B2/en not_active Expired
- 1993-12-23 EP EP94902952A patent/EP0675711B1/fr not_active Expired - Lifetime
- 1993-12-23 AT AT94902952T patent/ATE169215T1/de active
- 1993-12-23 TW TW088101847A patent/TW514531B/zh not_active IP Right Cessation
- 1993-12-23 HU HU9501812A patent/HU220215B/hu unknown
- 1993-12-23 ES ES94902952T patent/ES2122223T3/es not_active Expired - Lifetime
- 1993-12-23 TW TW082110927A patent/TW443935B/zh not_active IP Right Cessation
- 1993-12-23 HR HR9226905.9A patent/HRP931516B1/xx not_active IP Right Cessation
- 1993-12-23 DK DK94902952T patent/DK0675711T3/da active
- 1993-12-23 UA UA95062971A patent/UA39879C2/uk unknown
- 1993-12-23 WO PCT/GB1993/002646 patent/WO1994014426A1/fr active IP Right Grant
- 1993-12-23 RO RO95-01191A patent/RO119686B1/ro unknown
- 1993-12-23 SK SK828-95A patent/SK281924B6/sk not_active IP Right Cessation
- 1993-12-23 NZ NZ258995A patent/NZ258995A/en not_active IP Right Cessation
- 1993-12-23 IL IL10815493A patent/IL108154A/xx not_active IP Right Cessation
- 1993-12-23 MY MYPI93002823A patent/MY109990A/en unknown
-
1994
- 1994-04-03 SA SA94140644A patent/SA94140644B1/ar unknown
-
1995
- 1995-06-15 BG BG99723A patent/BG61932B1/bg unknown
- 1995-06-22 FI FI953139A patent/FI114007B/fi not_active IP Right Cessation
- 1995-06-22 NO NO19952522A patent/NO316745B1/no not_active IP Right Cessation
-
1997
- 1997-03-14 AU AU16279/97A patent/AU696662B2/en not_active Ceased
- 1997-11-19 US US08/974,248 patent/US6018080A/en not_active Expired - Lifetime
-
1998
- 1998-04-20 HK HK98103299A patent/HK1004086A1/xx not_active IP Right Cessation
-
1999
- 1999-10-04 US US09/411,381 patent/US6649659B1/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO316745B1 (no) | Mikrofluidiserte partikler av atovaquon, farmasoytisk preparat inneholdende slike partikler, fremgangsmate for deres fremstilling og fremgangsmate for fremstilling av preparatet | |
| US9254264B2 (en) | Compositions and uses thereof | |
| SK283632B6 (sk) | Farmaceutická kompozícia obsahujúca modafinil s definovanou veľkosťou častíc | |
| US8252326B2 (en) | Self-microemulsifying dosage forms of low solubility active ingredients such as co-enzyme Q10 | |
| WO2022222683A1 (fr) | Micro-émulsion de coenzyme q10, son procédé de préparation et son utilisation | |
| JPH04264029A (ja) | テポキサリンの眼科用水性微細乳濁液 | |
| FUKUSHIMA et al. | Preparation of and drug release from W/O/W type double emulsions containing anticancer agents | |
| KR20240134147A (ko) | 초미세 화합물 및 이의 제조 | |
| JP2022514276A (ja) | ワクチンアジュバント効果を有するフィラメント状ナノ粒子 | |
| KR20230048075A (ko) | 고체 미립자 물질의 제조 방법 | |
| Jitendra et al. | Formulation Development and Characterization of Modified Release Microspheres of Antianginal Drug | |
| CN108403629B (zh) | 一种尼莫地平口服长效悬浮液及其制备方法 | |
| Deepak et al. | Recent advancement, technology & applications of the multiple emulsions | |
| CN110548004A (zh) | 一种稳定的丁苯酞大容量注射液及其制备方法 | |
| CN111759834B (zh) | 萝卜硫素或其纳米粒在制备改善孕妇杂环胺摄入导致的胚胎神经系统发育不良药物中的应用 | |
| Kaewchada et al. | Encapsulation of Alpha-Tocopherol Using Polycaprolactone and Tween 20: Formulation and a Perspective for Scaling up Using Micro-Channel | |
| Shoaib | Development of dissolution medium of poorly soluble drug by using surfactants | |
| Mendes Cerdeira | Production and stabilization of nanosuspensions of poorly soluble drug substances |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: THE WELLCOME FOUNDATION LTD, GB |
|
| MK1K | Patent expired |